Lexicon Pharmaceuticals has made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers. Multiple studies support the cost efficacy of Inpefa for ...
Third quarter sales for Xermelo once again disappointed, as the company struggles to get payer coverage. Sota remains on track, and the FDA's briefing documents will be an important checkpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback